Đang chuẩn bị liên kết để tải về tài liệu:
Erlotinib treatment after platinum-based therapy in elderly patients with non-smallcell lung cancer in routine clinical practice – results from the ElderTac study

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

In this prospective non-interventional study, the effectiveness and tolerability of erlotinib in elderly patients with non-small-cell lung cancer (NSCLC) after ≥1 platinum-based chemotherapy were assessed. | Erlotinib treatment after platinum-based therapy in elderly patients with non-smallcell lung cancer in routine clinical practice results from the ElderTac study

TÀI LIỆU LIÊN QUAN

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: A comparative study

Erlotinib treatment after platinum-based therapy in elderly patients with non-smallcell lung cancer in routine clinical practice – results from the ElderTac study

Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): An open-label, non-randomized, multicenter, phase IV clinical trial